 | ||||||||||||
| ||||||||||||
| ||||||||||||
| ||||||||||||
 | ||||||||||||
 | ||||||||||||
 | ||||||||||||
| ||||||||||||||
|
|
 Sphingomyelin-Cholesterol Liposomes Significantly Enhance the Pharmacokinetic and Therapeutic Properties of Vincristine in Murine and Human Tumour Models. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Br J Cancer. Oct 1995;72(4):896-904. Preclinical Pharmacology, Toxicology and Efficacy of Sphingomyelin/Cholesterol Liposomal Vincristine for Therapeutic Treatment of Cancer. Webb MS, Logan P, Kanter PM, et al. Cancer Chemother Pharmacol. 1998;42(6):461-470. Preferential Extravasation and Accumulation of Liposomal Vincristine in Tumor Comparing to Normal Tissue Enhances Antitumor Activity. Shan S, Flowers C, Peltz CD, et al. Cancer Chemother Pharmacol. Aug 2006;58(2):245-255. Liposomal and Nonliposomal Drug Pharmacokinetics after Administration of Liposome-Encapsulated Vincristine and Their Contribution to Drug Tissue Distribution Properties. Krishna R, Webb MS, St Onge G, Mayer LD. J Pharmacol Exp Ther. Sep 2001;298(3):1206-1212. In Vivo Administration of Liposomal Vincristine Sensitizes Drug-Resistant Human Solid Tumors. Leonetti C, Scarsella M, Semple SC, et al. Int J Cancer. Jul 10 2004;110(5):767-774. Liposome-Encapsulated Vincristine, Vinblastine and Vinorelbine: A Comparative Study of Drug Loading and Retention. Zhigaltsev IV, Maurer N, Akhong QF, et al. J Control Release. May 5 2005;104(1):103-111. Marqibo®: Non-Hodgkin's Lymphoma (NHL) Sphingomyelin/Cholesterol Liposomal Vincristine: A New Formulation for an Old Drug. Boehlke L, Winter JN. Expert Opin Biol Ther. Apr 2006;6(4):409-415. Liposomal Vincristine in Relapsed Non-Hodgkin's Lymphomas: Early Results of an Ongoing Phase II Trial. Sarris AH, Hagemeister F, Romaguera J, et al. Ann Oncol. Jan 2000;11(1):69-72. Marqibo®: Acute Lymphoblastic Leukemia (ALL)
Phase II Study of Sphingosomal Vincristine in Patients with Recurrent or Refractory Adult Acute Lymphocytic Leukemia. Thomas DA, Sarris AH, Cortes J, et al. Cancer. Jan 1 2006;106(1):120-127. Marqibo®: Melanoma Pharmacokinetics and Urinary Excretion of Vincristine Sulfate Liposomes Injection in Metastatic Melanoma Patients. Bedikian AY, Vardeleon A, Smith T, Campbell S, Namdari R. J Clin Pharmacol. Jul 2006;46(7):727-737. Alocrest™: MOA/Pre-Clinical Optimization and Characterization of a Sphingomyelin-Cholesterol Liposome Formulation of Vinorelbine with Promising Antitumor Activity. Semple SC, Cullis PR. J Pharm Sci. May 2005;94(5). Optisomal Topotecan: MOA/Pre-Clinical Liposomal Encapsulation of Topotecan Enhances Anticancer Efficacy in Murine and Human Xenograft Models. Tardi P, Choice E, Masin D, Redelmeier T, Bally M, Madden TD. Cancer Res. Jul 1 2000;60(13):3389-3393. Drug Delivery Systems Drug Delivery Systems: Entering the Mainstream. Allen TM, Cullis PR. Science. Mar 19 2004;303(5665):1818-1822. |
||||||||||||
| ||||||||||||||
| ||||||||||||||
